- 6. Without  prejudice  to  the  economic  operator's  responsibility  for  the  data,  the  competent  authority  shall  verify  the confirmed data referred to in Section 1 of Part A of Annex VI.
- 7. The data entered pursuant to paragraph 1 of  this  Article  in  the  electronic  system  referred  to in  Article  30  shall  be accessible to the public.
- 8. The  competent  authority  may  use  the  data  to  charge  the  manufacturer,  the  authorised  representative  or  the importer a fee pursuant to Article 111.
## Article 32
## Summary of safety and clinical performance
- 1. For implantable devices and for class III devices, other than custom-made  or investigational devices, the manufacturer shall draw up a summary of safety and clinical performance.
The  summary  of  safety  and  clinical  performance  shall  be  written  in  a  way  that  is  clear  to  the  intended  user  and,  if relevant, to the patient and shall be made available to the public via Eudamed.
The draft  of  the  summary of  safety  and  clinical  performance  shall  be  part  of  the  documentation  to  be  submitted  to  the notified  body involved in the conformity assessment pursuant to Article 52 and shall be validated by that body. After its validation,  the  notified  body  shall  upload  the  summary  to  Eudamed.  The  manufacturer  shall  mention  on  the  label  or instructions for use where the summary is available.
- 2. The summary of safety and clinical performance shall include at least the following aspects:
- (a)   the  identification of  the device and the manufacturer, including the Basic UDI-DI and, if already issued, the SRN;
- (b)   the  intended purpose of the device and any indications, contraindications and target populations;
- (c)   a  description of  the  device,  including a  reference  to previous generation(s)  or  variants  if  such exist,  and  a  description of  the  differences,  as  well  as,  where  relevant,  a  description  of  any  accessories,  other  devices  and  products,  which  are intended to be used in combination with the device;
- (d)   possible diagnostic or  therapeutic alternatives;
- (e)   reference to any harmonised standards and CS applied;
- (f)   the  summary  of  clinical  evaluation  as  referred  to  in  Annex  XIV,  and  relevant  information  on  post-market  clinical follow-up;
- (g)   suggested profile and training for  users;
- (h)   information on any residual risks and any undesirable effects, warnings and precautions.
- 3. 